Sexual wellness is an important part of overall health, yet many individuals struggle with low libido or reduced sexual desire. PT-141, also known as bremelanotide, represents a breakthrough in addressing sexual desire — particularly because it works for both men and women and targets desire itself rather than the mechanics of arousal.
What is PT-141?
PT-141 (bremelanotide) is a melanocortin receptor agonist, a peptide that activates specific receptors in the central nervous system to increase sexual desire and arousal. Unlike phosphodiesterase-5 (PDE5) inhibitors like Viagra and Cialis, PT-141 does not work through blood vessel dilation or improved blood flow. Instead, it directly targets the neurological pathways involved in sexual desire.
How PT-141 Works
PT-141 activates melanocortin receptors in the brain, triggering a cascade of neurochemical events that enhance sexual motivation and desire. This mechanism makes it particularly effective for individuals with hypoactive sexual desire disorder (HSDD) and low libido — conditions where the desire itself is diminished, not necessarily the physical response.
PT-141 vs. Viagra and Cialis: Key Differences
This is where PT-141 truly stands out. Traditional erectile dysfunction medications approach sexual function from a purely vascular perspective:
- Viagra and Cialis: Improve blood flow to enhance erections but do not address desire or arousal on a neurological level
- PT-141: Targets sexual desire itself by working through the brain's arousal centers, making it ideal for those with low libido regardless of vascular function
For many individuals, low libido is the primary concern — and traditional medications do nothing to address it. PT-141 fills this critical gap.
Key advantage: PT-141 works for both men and women, making it one of the few peptides that effectively addresses sexual desire across genders. FDA studies have specifically examined PT-141 for treating HSDD in women.
Who Benefits from PT-141?
- Individuals with low libido or hypoactive sexual desire disorder (HSDD)
- Men and women who did not respond to PDE5 inhibitors
- Those with age-related decline in sexual desire
- Individuals seeking to enhance sexual motivation and arousal
- People experiencing desire issues related to hormonal changes or medical conditions
How PT-141 is Administered
PT-141 is administered as a subcutaneous injection — a quick, painless needle injection just under the skin. Most individuals take PT-141 approximately 10-20 minutes before anticipated sexual activity. The effects typically become noticeable within this window, making it convenient for planned intimacy.
Dosage and Timing
Medical consultation at Solas determines the appropriate dosage for your individual needs. Each injection is customized based on factors including body weight, response, and desired timing.
PT-141 at Solas: Pricing and Privacy
At Solas Health & Wellness in El Paso, PT-141 therapy is available at $190 per treatment. Beyond the treatment itself, we prioritize your privacy and discretion — a critical consideration for sexual wellness care. All consultations, treatments, and medical records are handled with complete confidentiality.
Explore PT-141 Therapy
in El Paso
Sexual wellness peptide protocols at Solas Health & Wellness. 6633 N Mesa St, Suite 508 · (915) 266-3174.
BOOK A CONSULTATIONWhy Choose PT-141?
For those struggling with low sexual desire, PT-141 offers a solution that traditional treatments cannot provide. It is particularly valuable for individuals who:
- Have tried PDE5 inhibitors without success
- Experience desire issues independent of vascular or mechanical limitations
- Are seeking a peptide-based approach to sexual wellness
- Value the option of a treatment that works for both men and women
Safety and Medical Supervision
PT-141 has shown a favorable safety profile in clinical research. As with all peptide therapies, proper medical supervision ensures appropriate dosing, monitoring, and management of any individual responses. At Solas, all PT-141 treatments are administered under the direct oversight of Celeste Cisneros, FNP-BC.